



BIODIEM LTD

ABN 20 096 845 993

Level 4,

100 Albert Rd,

South Melbourne, Victoria, 3205

Australia

Phone: +613 9692 7240

Web: www.biodiem.com

Announcement

Opal Biosciences' anti-infective technology profiled at 2015 Bio International Convention

Melbourne, 17th June 2015:

BioDiem CEO, Julie Phillips will profile the anti-infective technology of its new wholly-owned subsidiary, Opal Biosciences (Opal) at the [2015 BIO International Convention](#) (BIO) from June 15th-18th.

BIO is the world's largest biotech event and attracts more than 2,500 CEOs and 15,000 attendees. It covers a wide range of life science innovations, providing the ideal global stage to raise funds.

Julie will speak about the next generation of health challenges and will also introduce potential investors to Opal's promising next generation antimicrobial, Opal Technology.

Resistance to antibiotics is growing rapidly across the world, creating an urgent need for new treatments. Opal is currently developing two Opal Technology antimicrobial products, based on BioDiem's BDM-I technology:

- Opal-I, an injectable product, and
- Opal-T, which can be applied to skin.

Opal was established to help fast-track BioDiem's promising BDM-I studies and hold the BDM-I technology to allow outside investment in the project.

The Company is currently undertaking a capital raising of up to \$4 million to attract external investment in the technology. This investment will help expedite Opal's studies and Opal-I and Opal-T will be developed for commercialisation through sale of the technology to a larger company, potentially within two to three years.

The capital raising is open until 15 May 2016 and the incentives associated with early investment close on July 15, 2015. BioDiem shareholders will retain a stake in the BDM-I technology through BioDiem's shareholding in Opal. Those deemed to be "sophisticated investors" are also eligible to purchase more shares under the offer.

For more information, please contact BioDiem on: + 61 3 9692 7240 or email: info@biodiem.com.

The Opal offer is outlined in an Information Memorandum on Opal's website www.opalbiosciences.com. Please note that the offer is not open to the general public. The conditions of eligibility are included in the Explanatory Memorandum.

BioDiem shareholders have been invited to approve the assignment of BDM-I from BioDiem into Opal Biosciences at a shareholders' meeting to be held on July 6th at 5pm. Shareholders have been mailed the EGM documents.

View the BIO Opal Biosciences presentation

View Julie Phillips' presentation at the 2015 BIO International Convention which highlights Opal technology's exciting investment potential.

[Click to view Opal presentation](#)

Follow Opal on Twitter

Managing Director of Opal Biosciences, Julie Phillips shares the latest news from the anti-infectives sector and provides product development updates. Don't miss a tweet!

[Click to follow Opal on Twitter](#)

- ENDS -

About BioDiem Ltd

BioDiem is an Australian biopharmaceutical company that is focussed on developing and commercialising vaccines and infectious disease therapies. BioDiem's business model is to generate income from partnerships including with other *vaccine* and *infectious disease treatment* companies through existing and new licences to its LAIV vaccine and other technologies. Income comes from licence fees and royalties on sales.

BioDiem's lead technology is the LAIV (Live Attenuated Influenza Virus) vaccine technology used for production of seasonal and pandemic influenza vaccines and is given intranasally. This technology is licensed currently to two commercial partners, in India and China, and is licenced to the World Health Organisation as part of the Global Pandemic Influenza Action Plan to Increase Vaccine Supply. Serum Institute of India's Nasovac-S™ is based on BioDiem's technology and is already marketed in India. For additional information, please visit www.biodiem.com